Aralez Pharmaceuticals Inc. (ARZ) EPS Estimated At $-0.47

February 19, 2018 - By Rodney Autry

 Aralez Pharmaceuticals Inc. (ARZ) EPS Estimated At $ 0.47

Analysts expect Aralez Pharmaceuticals Inc. (TSE:ARZ) to report $-0.47 EPS on March, 12.They anticipate $0.01 EPS change or 2.08 % from last quarter’s $-0.48 EPS. After having $-0.46 EPS previously, Aralez Pharmaceuticals Inc.’s analysts see 2.17 % EPS growth. The stock increased 0.50% or $0.01 during the last trading session, reaching $2.03. About 10,895 shares traded. Aralez Pharmaceuticals Inc. (TSE:ARZ) has 0.00% since February 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical firm in the United States and Canada. The company has market cap of $135.78 million. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It currently has negative earnings. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.

More recent Aralez Pharmaceuticals Inc. (TSE:ARZ) news were published by: which released: “Aralez Pharmaceuticals: Rebound In Process” on September 29, 2017. Also published the news titled: “Aralez Pharmaceuticals: Expecting Positive Q3 Earnings Release” on October 30, 2017.‘s news article titled: “Aralez Pharmaceuticals: Update On Q3 Earnings Release” with publication date: November 13, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.